Anti-Human CD62L – Purified in vivo PLATINUM™ Functional Grade

Anti-Human CD62L – Purified in vivo PLATINUM™ Functional Grade

Product No.: C6270

[product_table name="All Top" skus="C2270"]

- -
- -
Clone
DREG56
Target
CD62L
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
TQ1, LAM1, LEU8, LNHR, LSEL, CD62L, LYAM1, PLNHR, LECAM1
Isotype
Mouse IgG1
Applications
B
,
FC
,
IF
,
IHC FF
,
in vivo
,
PhenoCycler®
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Recommended Isotype Controls
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this DREG56 antibody for staining cells in flow cytometry is ≤ 0.5 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
WB The suggested concentration for this DREG56 antibody for use in western blotting is 1-10 μg/ml.
Additional Applications Reported In Literature ?
IHC FF
IF
B
Additional Reported Applications For Relevant Conjugates ?
PhenoCycler-Fusion (CODEX)®
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone DREG56 recognizes an epitope on human CD62L.
Background
CD62L antibody, clone DREG56, recognizes CD62L, also known as L-selectin or LECAM-1, a 74-95 kDa type I transmembrane glycoprotein and cell adhesion molecule expressed on most circulating leukocytes1. Ligands for CD62L include CD34, GlyCAM-1, and MAdCAM-1, which require sialyation, fucosylation, and carbohydrate sulfation for recognition2,3. Ligand binding mediates tethering and rolling of leukocytes, facilitating entry into secondary lymphoid organs, including lymph nodes and Peyer’s patches, via high endothelial venules (HEVs)1. CD62L is also expressed on human embryo trophoblasts and has been proposed to play a role in human embryo implantation4.
Antigen Distribution
CD62L is expressed on most circulating leukocytes, including neutrophils, monocytes, T, B and NK cells, and human embryo trophoblasts.
Ligand/Receptor
CD34, GlyCAM, MAdCAM-1
Function
Leukocyte homing, leukocyte tethering, rolling
PubMed
NCBI Gene Bank ID
Research Area
Cell Adhesion
.
Cell Biology
.
Costimulatory Molecules
.
Immunology
.
Innate Immunity

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone DREG56 is a monoclonal antibody that specifically targets human CD62L (L-selectin), and in in vivo mouse studies, it is primarily used for functional blocking or depletion of human CD62L, often in models involving human cells or humanized mice rather than native mouse CD62L.

  • DREG56 binds to human CD62L, a glycoprotein expressed on human leukocytes (such as neutrophils, monocytes, T, B, and NK cells). CD62L plays a key role in the homing of lymphocytes to peripheral lymph nodes through high endothelial venules (HEVs).
  • In vivo uses in mouse studies typically involve humanized mouse models or mice engrafted with human immune cells. DREG56 is used to:
    • Block the function of human CD62L, preventing lymphocyte migration to lymph nodes by inhibiting binding to HEV.
    • Assess the role of CD62L-mediated homing in immune responses, trafficking, or disease models.
  • DREG56 does not cross-react with mouse CD62L, so its use in standard mouse models without human cell engraftment is not applicable. For native murine studies, a different anti-mouse CD62L antibody would be required.
  • Typical protocols involve systemic administration of DREG56 antibody in mice with human cells, followed by evaluation of immune cell distribution, trafficking, or experimental treatment outcome.

In summary, in vivo mouse use of DREG56 is limited to humanized settings or xenografts, where it is employed to block or study human CD62L-dependent processes. For studies of mouse CD62L, other antibodies are required.

Commonly Used Antibodies and Proteins with DREG56

DREG56 is a monoclonal antibody clone targeting CD62L (L-selectin), widely used in immunology research, especially in studies involving leukocyte adhesion, trafficking, and immune cell phenotyping. While the search results focus on DREG56 itself, several standard antibodies and proteins are commonly used alongside DREG56 in the literature, though not specifically listed in these sources. Based on the broader context of CD62L biology and typical experimental setups, the following are often used with DREG56:

Co-Staining Antibodies

  • CD44 antibody: CD44 is functionally linked to CD62L, with overlapping roles in cell adhesion and homing, particularly in lymphocyte migration and disease mechanisms. Co-staining with anti-CD44 helps distinguish cell subsets with different homing potentials (e.g., central vs. effector memory T cells).
  • CD4 and CD8 antibodies: These are frequently used in flow cytometry panels to define T cell subsets (helper and cytotoxic) when studying lymphoid cell populations. The cited protocol demonstrates co-staining of CD62L (DREG56) with CD4 using fluorescent conjugates.
  • CD19 and CD20 antibodies: Used to identify B cell populations, especially since CD62L is expressed on the majority of B cells. This allows for the delineation of naïve and memory B cell subsets.
  • CD14 and CD16 antibodies: For phenotyping monocytes and granulocytes, subsets which also express CD62L.
  • Isotype controls: Mouse IgG1 isotype controls, particularly from the same host as DREG56 (mouse IgG1), are essential for setting flow cytometry gates and verifying specificity.
  • Secondary detection antibodies: Goat anti-mouse IgG conjugated to fluorophores (e.g., Alexa Fluor® 488) are commonly used for detection when DREG56 is unlabeled.

Functional Assay Proteins

  • Glycoprotein ligands (e.g., GlyCAM-1, PSGL-1): Since CD62L is a lectin that mediates adhesion by binding sialylated glycoproteins, these ligands are sometimes used in functional adhesion assays to study CD62L’s interaction with endothelial cells.
  • Blocking antibodies: Other selectin family members (e.g., anti-CD62E, anti-CD62P) may be used in co-blocking experiments to dissect the specific contribution of CD62L in leukocyte recruitment.
  • Cytokines and chemokines: In vivo and in vitro models often incorporate cytokines (e.g., IL-2, IL-7) or chemokines (e.g., CCL21) to modulate CD62L expression and function on lymphocytes.

Negative Controls

  • Murine cells: When characterizing human samples, murine cells can serve as negative controls, provided there is no cross-reactivity between species.
  • Isotype controls: As noted, these are critical for ensuring signal specificity in both flow cytometry and functional assays.

Summary Table

Antibody/ProteinPurposeExample Use With DREG56
CD44Co-staining, phenotypingDistinguish memory T cell subsets
CD4, CD8T cell subset identificationDefine helper/cytotoxic T cells
CD19, CD20B cell subset identificationDelineate naïve/memory B cells
CD14, CD16Monocyte/granulocyte phenotypingStudy innate immune populations
Isotype control (IgG1)Specificity controlFlow cytometry gating
Goat anti-mouse IgGSecondary detectionFluorescent labeling
GlyCAM-1, PSGL-1Ligand for functional assaysAdhesion/migration studies
CD62E, CD62PBlocking/co-blockingLeukocyte recruitment studies
Cytokines/ChemokinesModulation of CD62L expressionIn vivo/in vitro stimulation
Murine cellsNegative controlSpecificity validation

These combinations are standard in immunology research focused on lymphocyte homing, adhesion, and migration, reflecting the central role of CD62L (detected by DREG56) in these processes. Always check for cross-reactivity and optimize panels based on specific experimental goals.

Based on the scientific literature cited across multiple research applications, clone DREG56 has generated several key findings that have advanced our understanding of CD62L/L-selectin biology and immune function.

Cellular Distribution and Expression Patterns

The DREG56 clone has been instrumental in characterizing the expression profile of CD62L across immune cell populations. Research has established that CD62L is expressed on neutrophils, monocytes, T- and B-lymphocyte subsets, and NK cells. The antibody recognizes a 74-95 kDa type I transmembrane glycoprotein that serves as a critical cell adhesion molecule on most circulating leukocytes.

Lymphocyte Homing and Tissue Selectivity

One of the most significant discoveries using DREG56 is its role in defining lymphocyte homing mechanisms. The clone specifically inhibits over 90% of binding between human lymphocytes and high endothelial venules (HEV) in frozen sections of peripheral lymphoid tissue, but notably not in mucosal lymphoid tissue. This finding established L-selectin as a human lymphocyte homing receptor with tissue-specific functions, particularly for peripheral lymph node HEV targeting.

Clinical Applications in Disease Research

The literature reveals extensive use of DREG56 in clinical research across multiple disease contexts:

Cancer Research: Studies have utilized the clone to investigate immune profiles in cancer patients, with research examining cellular immune responses and potential therapeutic targets.

Pediatric Medicine: Research has employed DREG56 to study immune development and function in pediatric populations, contributing to understanding age-related immune system variations.

Infectious Disease Studies: The clone has been valuable in examining immune responses during infections, including detailed flow cytometric analysis of leukocyte populations during disease progression.

COVID-19 Research Applications

Recent pandemic research has leveraged DREG56 for comprehensive immune profiling in COVID-19 patients. Studies have used high-dimensional flow cytometry with this clone to examine alterations in innate and adaptive immune compartments, revealing key myeloid signatures associated with severe disease. This work has contributed to understanding how immune cell characteristics and relative abundance change during COVID-19 progression.

Technical Validation Across Multiple Applications

The scientific literature demonstrates DREG56's versatility across various experimental techniques. Citations show successful applications in flow cytometry, western blotting, immunohistochemistry on frozen sections, and immunofluorescence. The clone has been validated for both research and clinical applications, with studies consistently demonstrating its reliability for detecting CD62L expression changes across different experimental conditions.

These findings collectively establish DREG56 as a critical research tool that has significantly advanced our understanding of immune cell trafficking, homing mechanisms, and disease-associated immune alterations across diverse clinical and research contexts.

There is no standardized in vivo dosing regimen for clone DREG56 (anti-human CD62L/L-selectin) across mouse models documented in the provided results. The available sources describe DREG56 primarily as a research-use-only (RUO) reagent for flow cytometry to detect human CD62L expression on human peripheral blood lymphocytes, not as a therapeutic or depleting antibody administered to living mice in preclinical models.

Key Context and Clarifications:

  • Dosing Regimens Not Reported: None of the retrieved sources specify intraperitoneal, intravenous, or other in vivo dosing instructions for clone DREG56 in mouse models, in contrast to well-characterized mouse-specific or functional antibodies such as anti-PD-1 or anti-CD3.

  • Usage in Research: DREG56 is routinely cited in protocols for ex vivo or in vitro applications—especially for flow cytometric staining of human cells, including those extracted from humanized mice. The protocols typically use very low amounts (e.g., 5–20 ?l of antibody per test for ~10? cells) and are not intended as dosing regimens for systemic administration.

  • Mouse Models and DREG56: In studies utilizing humanized mice (such as NSG mice engrafted with human PBMCs), DREG56 is used to analyze the expression of human CD62L on human T cells in mouse tissues by flow cytometry, not for in vivo modulation or depletion of target cells. No dosing regimens analogous to those for antibodies like anti-PD-1 (e.g., 100–200 ?g/mouse per injection) are described for DREG56.

  • Other Antibody Dosing: For reference, antibodies used functionally in mice (e.g., for depletion or signaling modulation) have published dose ranges and schedules. For example, anti-PD-1 antibodies are typically used at 100–500 ?g per mouse, often given intraperitoneally every 3–4 days, tailored for mouse immune targets and not for human-specific targets such as CD62L.

Summary Table: DREG56 vs. Common Functional Antibodies in Mouse Models

Antibody (Clone)TargetTypical Dose (in vivo, mouse)RouteComments
DREG56Human CD62LNot established for in vivoNot specifiedPrimarily ex vivo/in vitro for flow cytometry; no evidence of in vivo dosing
RMP1-14, 29F.1A12Mouse PD-1100–500 ?g/mouseIntraperitonealCancer/immunotherapy targets; published protocols
FGK4.5Mouse CD4050–300 ?g/mouseIP or IVFunctional depletion/activation in mouse models

If you seek in vivo dosing regimens for DREG56 in humanized mouse models or other contexts, this is not supported by the current literature or datasheets; DREG56 is not used for in vivo functional intervention in mice. Any proposed systemic use would require novel validation and justification.

If you meant flow cytometry staining protocols or require guidance for other anti-CD62L clones used in mouse (cross-reactive) models, please clarify.

References & Citations

1. Ivetic A, et al. (2019) Front Immunol. 10:1068
2. Varki A (1994) Proc Natl Acad Sci USA. 91(16):7390-7397
3. Rosen SD. (1999) Am J Pathol. 155(4):1013-1020
4. Genbacev OD, et al. (1003) Science. 299(5605):405-8
B
Flow Cytometry
IF
IHC FF
in vivo Protocol
PhenoCycler®
General Western Blot Protocol

Certificate of Analysis

- -
- -

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.